Ratings by Goldman Sachs (Andrea Newkirk)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/24/2026 | Kymera Therapeutics | KYMR | New Coverage | Early-Stage Biotech (N/A) |
115.47 (113.78) |
-1.46% | Details | |
| 9/24/2026 | Kodiak Sciences Inc. | KOD | New Coverage | Neutral (N/A) |
33.80 (89.40) |
164.5% | Details | |
| 9/24/2026 | Contineum Therapeutics | CTNM | New Coverage | Early-Stage Biotech (N/A) |
13.40 (8.37) |
-37.54% | Details | |
| 9/24/2026 | Tarsus Pharmaceuticals | TARS | New Coverage | Buy (N/A) |
77.08 (71.86) |
-6.77% | Details | |
| 9/24/2026 | Arrowhead Pharma | ARWR | New Coverage | Neutral (N/A) |
71.86 (59.46) |
-17.26% | Details | |
| 9/24/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Sell (N/A) |
11.09 (9.84) |
-11.27% | Details | |
| 9/24/2026 | Sagimet Biosciences Inc | SGMT | New Coverage | Sell (N/A) |
11.09 (9.84) |
-11.27% | Details | |
| 9/24/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
192.86 (196.49) |
1.88% | Details | |
| 9/24/2026 | Madrigal Pharmaceuticals | MDGL | New Coverage | Buy (N/A) |
518.83 (469.08) |
-9.59% | Details | |
| 9/24/2026 | Tarsus Pharmaceuticals | TARS | New Coverage | Buy (N/A) |
77.08 (71.86) |
-6.77% | Details | |
| 9/24/2026 | Krystal Biotech | KRYS | New Coverage | Buy (N/A) |
350.88 (320.90) |
-8.54% | Details | |
| 9/24/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
192.86 (196.49) |
1.88% | Details | |
| 9/24/2026 | Madrigal Pharmaceuticals | MDGL | New Coverage | Buy (N/A) |
518.83 (469.08) |
-9.59% | Details | |
| 9/24/2026 | Kodiak Sciences Inc. | KOD | New Coverage | Neutral (N/A) |
33.80 (89.40) |
164.5% | Details | |
| 9/24/2026 | Krystal Biotech | KRYS | New Coverage | Buy (N/A) |
350.88 (320.90) |
-8.54% | Details | |
| 9/24/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Buy (N/A) |
240.57 (212.63) |
-11.61% | Details | |
| 9/24/2026 | Jazz Pharmaceuticals | JAZZ | New Coverage | Buy (N/A) |
240.57 (212.63) |
-11.61% | Details | |
| 9/24/2026 | Iovanace Biotherapeutics | IOVA | New Coverage | Buy (N/A) |
10.64 (14.78) |
38.91% | Details | |
| 9/24/2026 | Iovanace Biotherapeutics | IOVA | New Coverage | Buy (N/A) |
10.64 (14.78) |
38.91% | Details | |
| 9/24/2026 | Insmed | INSM | New Coverage | Buy (N/A) |
120.82 (95.05) |
-21.33% | Details | |
| 9/24/2026 | Insmed | INSM | New Coverage | Buy (N/A) |
120.82 (95.05) |
-21.33% | Details | |
| 9/24/2026 | Arrowhead Pharma | ARWR | New Coverage | Neutral (N/A) |
71.86 (59.46) |
-17.26% | Details | |
| 9/24/2026 | Alkermes | ALKS | New Coverage | Neutral (N/A) |
43.29 (43.77) |
1.11% | Details | |
| 9/24/2026 | AbCellera Biologics | ABCL | New Coverage | Neutral (N/A) |
12.65 (11.97) |
-5.38% | Details | |
| 9/24/2026 | United Therapeutics Corp. | UTHR | New Coverage | Sell (N/A) |
497.59 (556.41) |
11.82% | Details | |
| 9/24/2026 | MeiraGTx Holdings plc | MGTX | New Coverage | Neutral (N/A) |
12.35 (10.02) |
-18.87% | Details | |
| 1/13/2026 | Revolution | RVMD | Maintain | Buy (N/A) |
|
Details | ||
| 9/30/2025 | Schrodinger | SDGR | New Coverage | Neutral (N/A) |
19.30 (24.05) |
24.61% | Details | |
| 7/15/2025 | Revolution | RVMD | New Coverage | Buy (N/A) |
38.02 (196.49) |
416.81% | Details | |
| 7/15/2025 | Alkermes | ALKS | New Coverage | Buy (N/A) |
30.28 (43.77) |
44.55% | Details | |
| 7/15/2025 | Iovanace Biotherapeutics | IOVA | Downgrade | Sell (Buy) |
1.87 (14.78) |
690.37% | Details | |
| 3/14/2025 | 89bio Inc. | ETNB | New Coverage | Neutral (N/A) |
8.35 (14.84) |
77.72% | Details |
